JP Morgan Chase’s Lipocine LPCN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-392
| Closed | -$2.97K | – | 7933 |
|
|
2026
Q1 | $2.97K | Buy |
+392
| New | +$3.42K | ﹤0.01% | 6957 |
|
|
2025
Q2 | – | Sell |
-11
| Closed | -$35 | – | 7409 |
|
|
2025
Q1 | $35 | Sell |
11
-1
| -8% | -$4 | ﹤0.01% | 7035 |
|
|
2024
Q4 | $59 | Hold |
12
| – | – | ﹤0.01% | 7099 |
|
|
2024
Q3 | $54 | Buy |
+12
| New | +$60 | ﹤0.01% | 7112 |
|
|
2024
Q2 | – | Sell |
-12
| Closed | -$62 | – | 7586 |
|
|
2024
Q1 | $62 | Buy |
12
+3
| +33% | +$12 | ﹤0.01% | 6988 |
|
|
2023
Q4 | $25 | Sell |
9
-174
| -95% | -$460 | ﹤0.01% | 7310 |
|
|
2023
Q3 | $538 | Buy |
183
+6
| +3% | +$25 | ﹤0.01% | 6715 |
|
|
2023
Q2 | $885 | Buy |
177
+1
| +0.6% | +$5 | ﹤0.01% | 6473 |
|
|
2023
Q1 | $1K | Hold |
176
| – | – | ﹤0.01% | 6529 |
|
|
2022
Q4 | $1K | Hold |
176
| – | – | ﹤0.01% | 6420 |
|
|
2022
Q3 | $1K | Hold |
176
| – | – | ﹤0.01% | 6342 |
|
|
2022
Q2 | $2K | Hold |
176
| – | – | ﹤0.01% | 6288 |
|
|
2022
Q1 | $4K | Hold |
176
| – | – | ﹤0.01% | 6351 |
|
|
2021
Q4 | $3K | Hold |
176
| – | – | ﹤0.01% | 6467 |
|
|
2021
Q3 | $3K | Hold |
176
| – | – | ﹤0.01% | 6293 |
|
|
2021
Q2 | $4K | Hold |
176
| – | – | ﹤0.01% | 6153 |
|
|
2021
Q1 | $5K | Hold |
176
| – | – | ﹤0.01% | 5865 |
|
|
2020
Q4 | $4K | Sell |
176
-777
| -82% | -$18.7K | ﹤0.01% | 5471 |
|
|
2020
Q3 | $22K | Buy |
953
+777
| +441% | +$20.6K | ﹤0.01% | 5124 |
|
|
2020
Q2 | $4K | Hold |
176
| – | – | ﹤0.01% | 5204 |
|
|
2020
Q1 | $1K | Hold |
176
| – | – | ﹤0.01% | 5209 |
|
|
2019
Q4 | $1K | Hold |
176
| – | – | ﹤0.01% | 5559 |
|
|
2019
Q3 | $8K | Hold |
176
| – | – | ﹤0.01% | 5528 |
|
|
2019
Q2 | $6K | Sell |
176
-777
| -82% | -$24K | ﹤0.01% | 5617 |
|
|
2019
Q1 | $37K | Buy |
+953
| New | +$29.2K | ﹤0.01% | 5233 |
|
|
2018
Q4 | – | Sell |
-5,613
| Closed | -$132K | – | 5814 |
|
|
2018
Q3 | $132K | Buy |
5,613
+3,329
| +146% | +$81.9K | ﹤0.01% | 4848 |
|
|
2018
Q2 | $50K | Buy |
+2,284
| New | +$54.4K | ﹤0.01% | 5079 |
|
|
2018
Q1 | – | Sell |
-533
| Closed | -$31K | – | 5519 |
|
|
2017
Q4 | $31K | Sell |
533
-797
| -60% | -$49.6K | ﹤0.01% | 5052 |
|
|
2017
Q3 | $90K | Buy |
+1,330
| New | +$96.2K | ﹤0.01% | 4331 |
|
|
2017
Q2 | – | Sell |
-11,393
| Closed | -$755K | – | 5095 |
|
|
2017
Q1 | $755K | Sell |
11,393
-689
| -6% | -$44.7K | ﹤0.01% | 3531 |
|
|
2016
Q4 | $756K | Sell |
12,082
-247
| -2% | -$15.6K | ﹤0.01% | 3567 |
|
|
2016
Q3 | $935K | Buy |
+12,329
| New | +$764K | ﹤0.01% | 3164 |
|
|
2016
Q2 | – | Sell |
-1,308
| Closed | -$226K | – | 4879 |
|
|
2016
Q1 | $226K | Buy |
+1,308
| New | +$223K | ﹤0.01% | 3574 |
|
|
2015
Q3 | – | Sell |
-2,065
| Closed | -$301K | – | 4002 |
|
|
2015
Q2 | $301K | Buy |
+2,065
| New | +$256K | ﹤0.01% | 3717 |
|
Other funds holding LPCN
SCM
IC
EP
BFM
JP Morgan Chase's LPCN Position: Q2 2026 in Review
JP Morgan Chase sold out of Lipocine (LPCN) in Q2 2026, closing a stake of 392 shares — an estimated $2.97K sold.
JP Morgan Chase first reported a position in LPCN in Q2 2015 and held it in 34 quarters. The position peaked at $935K in Q3 2016. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.
- JP Morgan Chase reported no remaining Lipocine position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 392 Lipocine shares in Q2 2026, an estimated $2.97K.
- JP Morgan Chase first reported a position in Lipocine in Q2 2015 and held it in 34 quarters.
- JP Morgan Chase's Lipocine position peaked at $935K in Q3 2016.
- 36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.